Analysis of information sources in references of the Wikipedia article "إختلال الميكروبيوم" in Arabic language version.
As reviewed in this report, synthetic biology shows potential in developing microorganisms for correcting pathogenic dysbiosis (gut microbiota-host maladaptation), although this has yet to be proven.
Several meta-analyses and systematic reviews have reported that patients treated with PPIs, as well as post-gastrectomy patients, have a higher frequency of small intestinal bacterial overgrowth (SIBO) compared to patients who lack the aforementioned conditions. Furthermore, there is insufficient evidence that these conditions induce Clostridium difficile infection. At this time, PPI-induced dysbiosis is considered a type of SIBO.
{{استشهاد بدورية محكمة}}: صيانة الاستشهاد: دوي مجاني غير معلم (link)Small intestinal fungal overgrowth (SIFO) is characterized by the presence of excessive number of fungal organisms in the small intestine associated with gastrointestinal (GI) symptoms. Candidiasis is known to cause GI symptoms particularly in immunocompromised patients or those receiving steroids or antibiotics. However, only recently, there is emerging literature that an overgrowth of fungus in the small intestine of non-immunocompromised subjects may cause unexplained GI symptoms. Two recent studies showed that 26 % (24/94) and 25.3 % (38/150) of a series of patients with unexplained GI symptoms had SIFO. The most common symptoms observed in these patients were belching, bloating, indigestion, nausea, diarrhea, and gas. The underlying mechanism(s) that predisposes to SIFO is unclear but small intestinal dysmotility and use of proton pump inhibitors has been implicated. However, further studies are needed; both to confirm these observations and to examine the clinical relevance of fungal overgrowth, both in healthy subjects and in patients with otherwise unexplained GI symptoms.
{{استشهاد بدورية محكمة}}: صيانة الاستشهاد: دوي مجاني غير معلم (link){{استشهاد بدورية محكمة}}: صيانة الاستشهاد: دوي مجاني غير معلم (link){{استشهاد بدورية محكمة}}: صيانة الاستشهاد: دوي مجاني غير معلم (link){{استشهاد بدورية محكمة}}: صيانة الاستشهاد: دوي مجاني غير معلم (link){{استشهاد بدورية محكمة}}: صيانة الاستشهاد: دوي مجاني غير معلم (link)As reviewed in this report, synthetic biology shows potential in developing microorganisms for correcting pathogenic dysbiosis (gut microbiota-host maladaptation), although this has yet to be proven.
Several meta-analyses and systematic reviews have reported that patients treated with PPIs, as well as post-gastrectomy patients, have a higher frequency of small intestinal bacterial overgrowth (SIBO) compared to patients who lack the aforementioned conditions. Furthermore, there is insufficient evidence that these conditions induce Clostridium difficile infection. At this time, PPI-induced dysbiosis is considered a type of SIBO.
{{استشهاد بدورية محكمة}}: صيانة الاستشهاد: دوي مجاني غير معلم (link)Small intestinal fungal overgrowth (SIFO) is characterized by the presence of excessive number of fungal organisms in the small intestine associated with gastrointestinal (GI) symptoms. Candidiasis is known to cause GI symptoms particularly in immunocompromised patients or those receiving steroids or antibiotics. However, only recently, there is emerging literature that an overgrowth of fungus in the small intestine of non-immunocompromised subjects may cause unexplained GI symptoms. Two recent studies showed that 26 % (24/94) and 25.3 % (38/150) of a series of patients with unexplained GI symptoms had SIFO. The most common symptoms observed in these patients were belching, bloating, indigestion, nausea, diarrhea, and gas. The underlying mechanism(s) that predisposes to SIFO is unclear but small intestinal dysmotility and use of proton pump inhibitors has been implicated. However, further studies are needed; both to confirm these observations and to examine the clinical relevance of fungal overgrowth, both in healthy subjects and in patients with otherwise unexplained GI symptoms.
{{استشهاد بدورية محكمة}}: صيانة الاستشهاد: دوي مجاني غير معلم (link){{استشهاد بدورية محكمة}}: صيانة الاستشهاد: دوي مجاني غير معلم (link){{استشهاد بدورية محكمة}}: صيانة الاستشهاد: دوي مجاني غير معلم (link){{استشهاد بدورية محكمة}}: صيانة الاستشهاد: دوي مجاني غير معلم (link)As reviewed in this report, synthetic biology shows potential in developing microorganisms for correcting pathogenic dysbiosis (gut microbiota-host maladaptation), although this has yet to be proven.
Several meta-analyses and systematic reviews have reported that patients treated with PPIs, as well as post-gastrectomy patients, have a higher frequency of small intestinal bacterial overgrowth (SIBO) compared to patients who lack the aforementioned conditions. Furthermore, there is insufficient evidence that these conditions induce Clostridium difficile infection. At this time, PPI-induced dysbiosis is considered a type of SIBO.
{{استشهاد بدورية محكمة}}: صيانة الاستشهاد: دوي مجاني غير معلم (link){{استشهاد بدورية محكمة}}: صيانة الاستشهاد: دوي مجاني غير معلم (link){{استشهاد بدورية محكمة}}: صيانة الاستشهاد: دوي مجاني غير معلم (link){{استشهاد بدورية محكمة}}: صيانة الاستشهاد: دوي مجاني غير معلم (link){{استشهاد بدورية محكمة}}: صيانة الاستشهاد: دوي مجاني غير معلم (link)